Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
347 Leser
Artikel bewerten:
(1)

Optimus HealthCare Services, Inc: Clinical Research Alliance Announces New Partnership With Quality Cancer Care, P.C.

Combining decades of expertise in delivering premier oncology care and expanding patient access to clinical trials.

NEW YORK, NY / ACCESSWIRE / February 9, 2023 / Clinical Research Alliance (CRA), a division of Optimus Healthcare Services, Inc. (OTC Pink:OHCS), announced a new strategic partnership with Quality Cancer Care, P.C., and Dr. Gardith Joseph. Together, CRA and Dr. Joseph aim to leverage her 21 years of experience specializing in oncology in Brooklyn, N.Y. with CRA's mission to expand clinical trials to an underserved population that historically has not been well represented in oncology clinical trials. Dr. Joseph has extensive experience with breast, gastrointestinal, and hematologic cancers. Dr. Joseph earned her medical degree from Universidad de Sevilla FOM and maintains affiliations with New York-Presbyterian, Brooklyn Methodist Hospital, and Brookdale Hospital Medical Center.

Dr. Joseph had this to say, referring to this emerging partnership; "CRA provides my patients with the choice of participating in clinical trials. I am excited at this opportunity to further assist our community."

CRA has a community-oriented mindset that is focused on helping underserved communities and patient populations. This mission is precisely what we aim to further achieve by bringing Dr. Joseph into the fold. CRA is comprised of dedicated physicians and healthcare professionals that are committed to providing patients with the opportunity to participate in clinical trials testing potential cancer treatments in their local communities. Dr. Joseph's decades of experience in the oncology field will help bring these clinical trials to her patients in Brooklyn. N.Y. CRA has participated in close to 200 decentralized trials delivering access to thousands of patients, and we look forward to the great work we can accomplish in conjunction with Dr. Joseph.

"We are pleased to partner with Dr. Joseph. She represents the physicians that CRA seeks strategic partnerships with. Dr. Joseph is committed to providing much needed care to the Brooklyn, N.Y. community. We look forward to providing her patients with access to much needed oncology clinical trials" said John Sganga, President and CEO of CRA.

About Clinical Research Alliance

CRA enables access to clinical trial research-making it easier for patients and providers to participate and accelerating the development of new and innovative cancer treatments that impact patient lives. By helping to provide state-of-the-art clinical trial research in a community setting, CRA also makes clinical research more accessible to underserved populations that enable faster enrollment, better retention and a patient population that is representative of real-world populations.

LinkedIn: clinical-research-alliance | Instagram: @clinicalresearchalliance | Facebook: @ClinicalResearchAlliance | https://www.clinicalresearchalliance.org/

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not a guarantee of future actions or performance. These forward-looking statements are based on information currently available to Optimus and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning Optimus's business are described in Periodic and Current Reports filed with the OTCIQ and the SEC. Optimus is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Cliff Saffron, Chief Financial Officer
csaffron@theoptimushealthcare.com
516-806-4201

SOURCE: Optimus Healthcare Services, Inc.

View source version on accesswire.com:
https://www.accesswire.com/738600/Clinical-Research-Alliance-Announces-New-Partnership-With-Quality-Cancer-Care-PC

© 2023 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.